Diego Miralles

President, Adaptive Therapeutics
2016 - 2017
Adaptive Biotechnologies is the leader in next generation sequencing (NGS) and expert bioinformatics to profile T- and B-cell receptors of the adaptive immune system. Adaptive Therapeutics is a new division of Adaptive Biotechnologies focused on the application of the Company’s proprietary technologies to determine the antigen-specificity of T- and B-cell receptors for use in therapies that will directly impact patient outcomes. Adaptive is exploring many potential therapeutic applications including adoptive cell therapy, passive immunization, novel target discovery, and antibody engineering.

2005 - 2016

Global Head Innovation
2015 - 2016
Over my 7 years in my leading role in Innovation at Johnson and Johnson, I was the founder of JLABS, a best in class corporate incubator in the life sciences and the Innovation Center system.
Head, West Coast Research Center, Janssen
2008 - 2016
Headed large R&D facility focused in pharmaceutical discoveries and early proof of concept clinical development. Site focused in Neuroscience and Pain, Metabolic, Cardiovascular, and Immunology.
Global Head of Innovation Janssen
2013 - 2015
Headed an entrepreneurial team within the Janssen Pharmaceutical Companies of Johnson & Johnson that created integrated care businesses and enabling technologies to transform the healthcare experience, improve outcomes and reduce healthcare costs. Based in the U.S. and Europe. The team created the Care4Today™ (www.care4today.com) master brand to reflect our commitment to transforming healthcare for the consumer.
VP, Scientific Affairs and Strategic Development, Tibotec Therapeutics
2007 - 2008
Was member of the Management Board, oversaw External Innovation, Virology, Drug Safety and Toxicology.
VP, Global Clinical Development, Tibotec Therapeutics
2005 - 2007

2000 - 2005

1993 - 2005

1998 - 2000

Independent Strategic Advisor, Biotech CEO, Board member, Lecturer